Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM).

Full DD Report for RYTM

You must become a subscriber to view this report.


Recent News from (NASDAQ: RYTM)

Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results
-- U.S. Food and Drug Administration (FDA) Agreed that Bardet-Biedl Syndrome (BBS) and Alström Syndrome are Included Under Existing Breakthrough Therapy Designation (BTD) for Setmelanotide -- -- Entered Licensing Agreement with Takeda for RM-853, Currently in Preclinical Dev...
Source: GlobeNewswire
Date: May, 14 2018 08:00
Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Keith Gottesdiener, M.D., Chief Executive Officer o...
Source: GlobeNewswire
Date: May, 09 2018 16:01
Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
 Longer-term data from open label study show reductions in hyperphagia and body weight In vitro analyses advance understanding of setmelanotide’s activity at the MC4 receptor, a part of a key pathway regulating energy homeostasis and appetite  BOSTON, May 09, 2018 (...
Source: GlobeNewswire
Date: May, 09 2018 16:01
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
INSYS launches mid-stage study of CBD in rare obesity disorder
INSYS Therapeutics ( INSY -0.7% ) initiates a Phase 2 clinical trial assessing its cannabidiol (CBD) oral solution for the potential treatment of Prader-Willi syndrome (PWS), a rare inherited disorder characterized by an insatiable appetite that leads to severe obesity. More news on: I...
Source: SeekingAlpha
Date: April, 27 2018 12:20
Institutional Top Ideas Series: Baker Brothers
In the last entry of this series, we took a look at top ideas from Scopia Capital Management (whose performance significantly exceeded that of the IBB during the time frame we looked at). We also took into account the fact that they are a long/short market neutral fund with several outsize...
Source: SeekingAlpha
Date: April, 25 2018 05:17
Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co., Oaktree Specialty Lending, Rhythm Pharmaceuticals, Cellectis S.A, and Travelport Worldwide - Fundamental Analysis, Key Performance Indications
NEW YORK, April 11, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ctrip.com International, Ltd. (NASDAQ:CTRP), JA Solar Holdings, Co., Ltd...
Source: GlobeNewswire
Date: April, 11 2018 07:40
Rhythm Pharmaceuticals Diversifies As A Major Catalyst Approaches
Rhythm Pharmaceuticals Inc ( RYTM ) is a biopharmaceutical company, developing drugs for rare genetic disorders of obesity, which went public via IPO in October, 2017. RYTM's lead pipeline member is setmelanotide, a peptide drug which activates the melanocortin-4 receptor (MC4-R). Activat...
Source: SeekingAlpha
Date: April, 09 2018 11:00
Rhythm Pharma in-licenses PWS candidate from Takeda
Rhythm Pharmaceuticals ( RYTM -3.5% ) acquires exclusive global rights to Takeda Pharmaceutical Company's ( OTCPK:TKPYY ) T-3525770 (now RM-853), an orally available inhibitor of an enzyme called ghrelin o-acyltransferase (GOAT), in preclinical development for Prader-Willi syndrome  ...
Source: SeekingAlpha
Date: April, 02 2018 10:34
Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome
-- Oral Ghrelin O-Acyltransferase (GOAT) Inhibitor Complements and Expands Efforts in Prader-Willi Syndrome -- -- In Preclinical Models, Prevented Body Weight Gain and Reduced Fat Mass -- -- Rhythm Expects to File Investigational New Drug Application in First Quarter of 2020 -- BOST...
Source: GlobeNewswire
Date: April, 02 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1730.3931.8833.1630.12146,974

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-1815,62695,76916.3163Cover
2018-05-1710,37937,54927.6412Cover
2018-05-1621,17842,12050.2802Short
2018-05-1514,76524,68259.8209Short
2018-05-1421,64341,77851.8048Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RYTM.


About Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)

Logo for Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: RYTM)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 30 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 02 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 14 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 12 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: February, 07 2018

       

       


      Daily Technical Chart for (NASDAQ: RYTM)

      Daily Technical Chart for (NASDAQ: RYTM)


      Stay tuned for daily updates and more on (NASDAQ: RYTM)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: RYTM)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RYTM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of RYTM and does not buy, sell, or trade any shares of RYTM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/